Industry Symposium:
A CDK4/6i is a ‘once in a lifetime treatment’ for patients with
HR +ve HER2 -ve breast cancer
Supported by Novartis

Saturday, October 15, 2022                                                    Hall B (Great Hall 2)
10:00 – 11:00
Admission to this symposium is included as part of the congress registration

Chairperson: Nicholas Wilcken, Sydney, Australia
Richard de Boer, Melbourne, Australia
Affirmative: Catherine Shannon, Brisbane, Australia
Against: Andrew Redfern, Perth, Australia
Skip to content